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1607-551X/Copyright ª 2014, KaohsiuAbstract Diabetes mellitus (DM) has been reported to increase the risk of complications of
liver cirrhosis of any etiology and subsequent survival. However, the impact of DM on the
development of gastroesophageal variceal bleeding (GEVB) remains unclear. We aimed to
elucidate whether DM is an independent risk factor for GEVB among cirrhotic patients. A to-
tal of 146 consecutive patients with liver cirrhosis (Child-Pugh Class A, n Z 75; Class B,
n Z 40; and Class C, n Z 31) were prospectively enrolled. Data on clinical and biochemical
characteristics and history of ascites, GEVB, hepatic encephalopathy, and spontaneous bac-
terial peritonitis were retrospectively reviewed. Of these 146 patients, 37 (25%) had DM. Pa-
tients with DM had significantly higher ratio of Child-Pugh Class B/C (p Z 0.043), renal
insufficiency (p Z 0.002), and history of GEVB (p Z 0.006) compared with non-DM patients.
GEVB was associated with Child-Pugh Class B/C (p Z 0.001), ascites (p Z 0.002), hepatic
encephalopathy (p Z 0.023), and low platelet counts (p < 0.001). Based on stepwise multi-
ple logistic regression analysis, Child-Pugh class B/C [odds ratio (OR)Z 4.90, pZ 0.003] and
DM (OR Z 2.99, p Z 0.022) were identified as independent predictors of GEVB. In the sub-
group analysis, DM significantly correlated with GEVB in patients with Child-Pugh Class Aeclare no conflicts of interest.
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516 C.-H. Yang et al.(p Z 0.042), but not in patients with Child-Pugh Class B/C (p Z 0.128). DM is independently
associated with GEVB in cirrhotic patients, especially in those with Child-Pugh Class A.
Copyright ª 2014, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Cirrhosis represents the final common pathway of virtually
all chronic liver diseases. Patients with liver cirrhosis are at
risk of developing many potential life-threatening compli-
cations. The 1-year mortality rate in patients with
compensated cirrhosis is 1e3.4%, whereas the rate is
20e57% in patients with decompensated cirrhosis [1e3].
Ascites, spontaneous bacterial peritonitis (SBP), hepatic
encephalopathy, and gastroesophageal variceal bleeding
(GEVB) are the most common cirrhotic complications,
which are generally thought to be related to portal hyper-
tension. Of these complications, GEVB is undoubtedly the
most critical event with the highest risk of mortality [4].
Cirrhosis causes impaired metabolic homeostasis of
glucose and leads to “hepatogenous diabetes” [5].
Approximately 30% of cirrhotic patients suffer from this
metabolic disorder [6]. There is growing evidence that
either hepatogenous diabetes or type 2 diabetes mellitus
(DM) is associated with an increased risk of cirrhotic com-
plications. The Verona Diabetes Study, a population-based
study on more than 7000 patients with type 2 DM, found
an increased risk of death from chronic liver disease and
cirrhosis compared with the general population [7]. In
addition, several studies have demonstrated an increased
incidence of DM, ranging from two- to four-fold, among
patients with hepatocellular carcinoma (HCC) [8e10].
Recently, insulin resistance, a prominent feature of type
2 DM, has been proven to be a predictor of portal hyper-
tension [11] and the development of esophageal varices
[12]. However, to our knowledge, there are no studies to
demonstrate the association between DM and GEVB. The
aim of our study was to elucidate whether DM is an inde-
pendent risk factor for GEVB in cirrhotic patients.Methods
From February 2013 to May 2013, a total of 146 patients
with liver cirrhosis were consecutively enrolled in our
outpatient clinic prospectively. The diagnosis of cirrhosis
and DM, the severity and complications of cirrhosis, and
comorbidity were retrospectively reviewed from January
2008 to January 2013. The complications of cirrhosis were
mainly focused on ascites, SBP, hepatic encephalopathy,
and GEVB. The diagnosis of DM should be earlier to the
onset of GEVB.
Clinical diagnosis of cirrhosis was based on repeated
ultrasound findings suggestive of cirrhosis at least twice 3
months apart, supplemented with clinical criteria, such as
thrombocytopenia or other signs of portal hypertension
[13]. The diagnosis of DM was mainly based on the AmericanDiabetes Association revised criteria, which include the
following [14]: fasting plasma glucose level  7.0 mmol/L
(126 mg/dL), symptoms of hyperglycemia and casual
plasma glucose  11.1 mmol/L (200 mg/dL), and glycated
hemoglobin (HbA1C)  6.5% [15]. Those on regular oral
antidiabetic agents or under insulin injection were also
considered as DM patients. The HbA1c data were recorded
within 3 months prior to the GEVB episode in the GEVB
group, whereas in the non-GEVB group, an average of three
random values was taken.
GEVB should meet the following criteria: clinical signs of
bleeding from gastrointestinal tract and endoscopic signs of
active or recent bleeding or large varices with a red-colored
sign without other bleeding sources. We excluded cases
with incomplete chart recordings and HCC. The study pro-
tocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki and was approved by the Ethics
Committee of Chang Gung Memorial Hospital, Kaohsiung,
Taiwan. All patients gave written informed consent before
enrollment.
Continuous variables were presented as
mean  standard deviation, and the categorical data were
expressed as number (percentage). Chi square test, Fisher’s
exact test, and the ManneWhitney U test were used
wherever appropriate. Independent factors predicting
GEVB were identified using stepwise multiple logistic
regression analysis. A p value <0.05 was considered sta-
tistically significant.
Results
Baseline features of the 146 patients are shown in Table 1.
There were 82 men and 64 women, with a mean age of 61
years. Overall, 37 of 146 patients (25%) had DM. The eti-
ology of liver cirrhosis included alcoholism, chronic hepa-
titis B, chronic hepatitis C, autoimmune hepatitis, primary
biliary cirrhosis, and cryptogenic cirrhosis. Seventy-five
patients were in Child-Pugh Class A (52%), 40 in Class B
(27%), and 31 in Class C (21%), respectively.
Table 2 shows the comparison of the clinical variables
and cirrhotic complications between diabetic and nondia-
betic patients. Patients with DM were significantly older
(pZ 0.022) and had a higher ratio of chronic kidney disease
(pZ 0.002), Child-Pugh Class B/C (pZ 0.043), and history
of GEVB (p Z 0.006) compared with non-DM patients.
Table 3 compares the clinical characteristics between
patients with and without GEVB. Patients with a history of
GEVB had lower platelet counts, a lower albumin level,
higher total bilirubin level, a prolonged prothrombin time,
and an increasing proportion of ascites and encephalopathy
than did non-GEVB patients, and therefore, the ratio of
Child-Pugh Class B/C was correspondingly higher. Besides,
Table 2 Comparison of clinical characteristics and
cirrhotic complications between DM and non-DM patients.
Characteristics DM
(n Z 37)
Non-DM
(n Z 109)
p
Age (y) 64  10 60  12 0.022
Male 21 (57) 61 (56) 0.544
BMI (kg/m2) 25.8  4.4 25.4  4.2 0.744
CKD 12 (32) 11 (10) 0.002
Anti-HCV Ab(þ) 14 (38) 47 (43) 0.358
Child-Pugh
class B/C
23 (62) 48 (40) 0.043
AST (IU/L) 81  72 72  112 0.064
ALT (IU/L) 67  74 55  97 0.338
Platelets (109/L) 98  53 110  54 0.150
PT (s) 13.2  4.1 12.7  3.3 0.143
Albumin (mg/dL) 3.3  0.7 3.5  0.8 0.076
Total bilirubin
(mg/dL)
3.5  0.7 2.2  2.8 0.429
Cirrhotic complications
Ascites 19 (51) 39 (36) 0.070
SBP 1 (3) 4 (4) 0.626
Encephalopathy 16 (43) 37 (34) 0.206
GEVB 12 (32) 13 (12) 0.006
Data are presented as n (%) or mean  SD.
ALT Z alanine aminotransferase; anti-HCV Ab Z antibody to
hepatitis C virus; AST Z aspartate aminotransferase;
BMI Z body mass index; CKD Z chronic kidney disease;
DM Z diabetes mellitus; GEVB Z gastroesophageal variceal
bleeding; PTZ prothrombin time; SBPZ spontaneous bacterial
peritonitis.
Table 1 Clinical characteristics of the patients.
Characteristics (n Z 146)
Age (y) 61  12
Male 82 (56)
DM 37 (25)
BMI (kg/m2) 25.5  4.3
CKD 23 (16)
Etiology
Alcoholism 18 (12)
HBV 48 (33)
HCV 46 (32)
HBV þ HCV 13 (9)
HBV þ HCV þ alcoholism 2 (1)
AIH/PBC/cryptogenic 19 (13)
Laboratory
Platelets (109/L) 106  54
PT (s) 12.8  3.5
Creatinine (mg/dL) 1.1  1.1
AST (IU/L) 74  103
ALT (IU/L) 58  91
Albumin (mg/dL) 3.5  1.0
Total bilirubin (mg/dL) 2.5  4.1
Child-Pugh classification
A 75 (52)
B 40 (27)
C 31 (21)
Data are presented as n (%) or mean  SD.
AIHZ autoimmune hepatitis; ALTZ alanine aminotransferase;
AST Z aspartate aminotransferase; BMI Z body mass index;
CKD Z chronic kidney disease; DM Z diabetes mellitus;
HBV Z hepatitis B virus; HCV Z hepatitis C virus;
PBC Z primary biliary cirrhosis; PT Z prothrombin time.
Table 3 Comparison of clinical characteristics between
patients with and without GEVB.
Characteristics GEVB
(n Z 25)
Non-GEVB
(n Z 121)
p
Age (y) 59  13 61  11 0.544
Male 18 (72) 64 (53) 0.061
DM 12 (48) 25 (21) 0.006
HBA1c  7a 8/12 (67) 9/25 (36) 0.081
CKD 6 (24) 17 (14) 0.171
Child-Pugh
class B/C
20 (80) 51 (42) 0.001
Ascites 17 (68) 41 (34) 0.002
Encephalopathy 14 (56) 39 (32) 0.023
AST (IU/L) 93  146 71  93 0.680
ALT (IU/L) 46  55 61  97 0.151
Platelets (109/L) 73  29 114  55 <0.001
PT (s) 12.9  1.3 12.8  3.8 0.012
Albumin (mg/dL) 3.2  0.5 3.5  0.8 0.016
Total bilirubin
(mg/dL)
3.6  6.2 2.3  3.4 0.003
Data are presented as n (%) or mean  SD.
ALT Z alanine aminotransferase; AST Z aspartate amino-
transferase; CKD Z chronic kidney disease; DM Z diabetes
mellitus; GEVB Z gastroesophageal variceal bleeding;
PT Z prothrombin time.
a Only available in 37 diabetic patients.
DM and GEV bleeding risk 517the GEVB group also had a higher rate of DM. In patients
with Child-Pugh Class A, only DM and prolonged prothrom-
bin time were significantly associated with GEVB (Table 4).
Among diabetic patients, the GEVB group had a higher rate
(67%) of poor glycemic control (HBA1c  7) compared with
the non-GEVB group (36%; p Z 0.081; Table 3). Although
this could not reach statistical significance, a similar ten-
dency could be found in patients with Child-Pugh Class A
(Table 4).
Based on stepwise multiple logistic regression analysis of
factors (age, sex, DM, Child-Pugh classification, and
platelet < 105/mL), DM [odds ratio (OR) Z 2.99, 95% con-
fidence interval (CI)Z 1.170e7.660, pZ 0.022] and Child-
Pugh Class B/C (OR Z 4.90, 95% CI Z 1.697e14.162,
p Z 0.003) were found to be independent predictors of
GEVB (Table 5). In the subgroup analysis, DM significantly
correlated with GEVB in patients with Child-Pugh Class A
(p Z 0.042), but not in patients with Child-Pugh Class B/C
(p Z 0.128).
Discussion
Cirrhosis may contribute to the development of DM through
numerous factors. With the development of portal hyper-
tension, blood shunting redirects blood away from hepa-
tocytes and results in reduced insulin clearance with
Table 4 Comparison of Child-Pugh A patients with GEVB
versus those without GEVB.
Characteristics GEVB
(n Z 5)
Non-GEVB
(n Z 70)
p
Age (y) 56  11 62  12 0.303
Male 3 (60) 36 (53) 0.539
DM 3 (60) 11 (16) 0.042
HBA1c  7a 3/3 (100) 4/11 (36) 0.096
CKD 0 (0) 2 (3) 0.870
AST (IU/L) 39  8 51  32 0.653
ALT (IU/L) 29  17 58  61 0.247
Platelets (109/L) 87  20 129  56 0.065
PT (s) 11.8  0.8 11.0  0.6 0.031
Albumin (mg/dL) 3.9  0.3 4.1  0.4 0.144
Total bilirubin
(mg/dL)
0.9  0.2 1.0  0.5 0.688
Data are presented as n (%) or mean  SD.
ALT Z alanine aminotransferase; AST Z aspartate amino-
transferase; CKD Z chronic kidney disease; DM Z diabetes
mellitus; GEVB Z gastroesophageal variceal bleeding;
PT Z prothrombin time.
a Only available in 37 diabetic patients.
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insulinemia may contribute to the development of insulin
resistance through the downregulation of insulin receptors
[17]. In our study, patients with DM were significantly older
and had a higher ratio of Child-Pugh Class B/C than did non-
DM patients, whereas there was no difference in body mass
index between these two groups. This finding supported the
previous observation that hepatogenous diabetes differs
from type 2 diabetes in that there is less association with
traditional risk factors such as body mass index and family
history of diabetes [18]. In addition, there was no signifi-
cant difference in the antihepatitis C virus (anti-HCV)
antibody positive rate between DM and non-DM patients.
This could be explained either by the inclusion of patients
with advanced liver disease (48% of Child-Pugh Class B/C) or
the small case numbers in the HCV group.
Several studies have shown that DM increases the risk of
complications associated with liver cirrhosis regardless of
etiology and subsequently reduces survival [7,18,19]. DMTable 5 Univariate analyses and stepwise multivariate analyse
Univariate analyses
Odds ratio
(95% CI)
All patients
Age (per 1-y increase) 0.98 (0.95e1.02)
Male sex 2.29 (0.89e5.88)
DM 3.55 (1.44e8.72)
CKD 1.93 (0.68e5.53)
Child-Pugh
class B/C
5.49 (1.93e15.60)
Platelets (<105/mL) 3.80 (1.42e10.18)
CI Z confidence interval; CKD Z chronic kidney disease; DM Z diabcan either exacerbate deterioration of liver function or
accelerate the production of fibrosis leading to severe liver
failure [20]. In addition, DM may enhance the incidence of
serious infections, such as SBP in cirrhotic patients that are
associated with increased mortality [21,22]. The principal
finding of this study was that the incidence of GEVB was
significantly higher in cirrhotic patients with DM than in
cirrhotic patients without DM (32% vs. 12%, respectively;
p Z 0.006). Although we noticed an increasing trend of
hepatic encephalopathy and ascites, there was no signifi-
cant difference in this regard between DM and non-DM
patients, suggesting that GEVB might be the most crucial
factor to decide the outcome in cirrhotic patients with DM.
Previous studies have shown that the course of
compensated cirrhosis is relatively slow, whereas the
mortality appears to be higher in patients with GEVB or
developing HCC [23,24]. A recent study has estimated that
the 5-year cumulative incidences of mortality, hepatic
decompensation, and HCC were significantly higher in HCV-
related compensated cirrhotic patients with esophageal
varices than in those without esophageal varices [24]. It is
particularly noteworthy that DM was significantly corre-
lated with GEVB in our compensated cirrhotic patients, but
not with Child-Pugh Class B/C. This finding suggested that
DM might be associated with early mortality among patients
with compensated cirrhosis through the increasing inci-
dence of GEVB.
It is well-known that insulin resistance is a prominent
feature of type 2 DM [25,26]. Insulin is able to modulate the
endothelial synthesis of nitric oxide and endothelin [27,28]
to induce the production of tumor necrosis factor alpha and
connective growth factor and to stimulate hepatic stellate
cells [29,30], the effectors in the pathogenesis of liver
fibrosis and portal hypertension [31]. In addition, hyper-
glycemia also induces splanchnic hyperemia and increases
portal pressure and bacterial translocation, which also in-
crease the risk of variceal hemorrhage [32e34]. Recently,
Gundling et al [35] demonstrated that optimization of dia-
betic metabolic conditions is not only important to avoid
typical diabetic late complications but also cirrhosis-
associated complications, such as gastrointestinal
bleeding, hepatic encephalopathy, or the occurrence of
HCC. However, these findings should be further confirmed
by other large-scale controlled studies.s of factors associated with GEVB.
Stepwise multivariate analyses
p Odds ratio
(95% CI)
p
0.385 d d
0.085 d d
0.006 2.99 (1.17e7.66) 0.022
0.220 d d
0.001 4.90 (1.70e14.16) 0.003
0.008 d d
etes mellitus; GEVB Z gastroesophageal variceal bleeding.
DM and GEV bleeding risk 519There are some limitations in our study. First, the
analysis was carried out in a relatively small number of
patients, and it will be interesting to determine whether
this association holds true in larger groups of patients as
well. Second, subclinical DM (patients with normal fasting
glucose levels and no history of DM in whom the oral glucose
tolerance test was suggestive of DM) was not studied in our
patients classified as non-DM patients. Although a previous
study has shown that insulin resistance, regardless of the
presence of diabetes, significantly predicts the presence of
esophageal varices in chronic hepatitis C patients with
Child-Pugh class A cirrhosis [12], whether subclinical DM is
associated with GEVB remains to be further clarified.
Conclusion
In conclusion, DM was found to be independently associated
with GEVB, especially in patients with Child-Pugh Class A. In
cirrhotic patients with DM, routine and close endoscopic
follow-up for GEVB should be considered. We also found
that the risk of GEVB increases in patients with poor gly-
cemic control. However, further prospective studies are
necessary to confirm our findings.
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